tamoxifen Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2561 10540-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tamoxifen
  • tamoxifen citrate
  • tamoxifene
  • tamoxifene citrate
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
  • Molecular weight: 371.52
  • Formula: C26H29NO
  • CLOGP: 6.82
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.56
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.18 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1977 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1252.27 30.59 308 2604 11820 2343353
Metastases to bone 1127.11 30.59 211 2701 2058 2353115
Metastases to liver 703.99 30.59 149 2763 2792 2352381
Death 520.62 30.59 258 2654 81210 2273963
Breast cancer 516.73 30.59 146 2766 9349 2345824
Disease progression 480.20 30.59 158 2754 16937 2338236
Breast cancer metastatic 463.38 30.59 100 2812 2044 2353129
Metastases to lung 398.01 30.59 85 2827 1646 2353527
Metastases to lymph nodes 365.90 30.59 72 2840 908 2354265
Metastasis 339.41 30.59 67 2845 859 2354314
Breast cancer recurrent 303.02 30.59 59 2853 700 2354473
Uterine polyp 281.95 30.59 50 2862 338 2354835
Acute myeloid leukaemia 262.77 30.59 66 2846 2644 2352529
Neoplasm progression 254.13 30.59 72 2840 4596 2350577
Hot flush 231.58 30.59 74 2838 7125 2348048
Endometrial hyperplasia 186.92 30.59 33 2879 216 2354957
Second primary malignancy 178.58 30.59 40 2872 966 2354207
Arthralgia 165.95 30.59 107 2805 54178 2300995
Pseudocirrhosis 154.37 30.59 25 2887 88 2355085
Fatigue 146.11 30.59 118 2794 84755 2270418
Neuropathy peripheral 144.79 30.59 59 2853 11373 2343800
Pulmonary embolism 143.15 30.59 67 2845 18016 2337157
Metastases to spine 142.02 30.59 28 2884 354 2354819
Endometrial hypertrophy 139.29 30.59 23 2889 94 2355079
Breast cancer female 130.36 30.59 33 2879 1357 2353816
Endometrial cancer 127.31 30.59 28 2884 619 2354554
Tumour marker increased 112.67 30.59 26 2886 718 2354455
Dyspnoea 103.61 30.59 94 2818 78639 2276534
Metastases to central nervous system 102.73 30.59 30 2882 2118 2353055
Asthenia 101.72 30.59 75 2837 46851 2308322
Pleural effusion 100.86 30.59 46 2866 11622 2343551
Hepatic steatosis 98.92 30.59 32 2880 3181 2351992
Metastases to skin 98.86 30.59 19 2893 208 2354965
Hysteroscopy 93.93 30.59 14 2898 23 2355150
Diarrhoea 93.12 30.59 91 2821 83473 2271700
Disease recurrence 92.68 30.59 31 2881 3420 2351753
Insomnia 91.42 30.59 56 2856 25731 2329442
Endometrial atrophy 89.17 30.59 14 2898 38 2355135
Pulmonary mass 88.14 30.59 26 2886 1900 2353273
Hysterectomy 87.45 30.59 25 2887 1635 2353538
Invasive ductal breast carcinoma 86.88 30.59 22 2890 904 2354269
Anaemia 83.02 30.59 59 2853 34733 2320440
Osteonecrosis of jaw 80.19 30.59 35 2877 7961 2347212
Recurrent cancer 79.91 30.59 17 2895 319 2354854
Hepatic cirrhosis 78.84 30.59 25 2887 2328 2352845
Vaginal haemorrhage 77.98 30.59 30 2882 4950 2350223
Depression 77.18 30.59 52 2860 28080 2327093
Portal hypertension 76.77 30.59 18 2894 533 2354640
Oestrogen receptor positive breast cancer 76.31 30.59 12 2900 33 2355140
Bone pain 76.24 30.59 35 2877 8961 2346212
Visual acuity reduced 76.18 30.59 30 2882 5268 2349905
Nausea 72.65 30.59 92 2820 112097 2243076
Disturbance in attention 70.70 30.59 29 2883 5656 2349517
Deep vein thrombosis 69.81 30.59 37 2875 12895 2342278
Uterine cancer 69.57 30.59 18 2894 806 2354367
Myelodysplastic syndrome 68.74 30.59 23 2889 2537 2352636
Vomiting 68.68 30.59 72 2840 71530 2283643
Sarcoma uterus 68.28 30.59 11 2901 37 2355136
Neutropenia 66.77 30.59 43 2869 21505 2333668
Tinnitus 66.61 30.59 27 2885 5108 2350065
Endocervical curettage 65.81 30.59 9 2903 4 2355169
Ovarian cancer 65.69 30.59 19 2893 1294 2353879
Pain 64.34 30.59 65 2847 61792 2293381
Pain in extremity 64.14 30.59 55 2857 42485 2312688
Metastases to the mediastinum 61.25 30.59 11 2901 80 2355093
Onycholysis 59.66 30.59 13 2899 274 2354899
Myalgia 58.91 30.59 41 2871 23292 2331881
Uterine leiomyoma 58.38 30.59 18 2894 1527 2353646
Carbohydrate antigen 15-3 increased 57.86 30.59 11 2901 113 2355060
Drug resistance 56.54 30.59 20 2892 2604 2352569
Paraesthesia 56.19 30.59 39 2873 22049 2333124
Acute promyelocytic leukaemia 55.39 30.59 12 2900 246 2354927
Uterine dilation and curettage 54.98 30.59 12 2900 255 2354918
Breast mass 54.88 30.59 16 2896 1120 2354053
Arthropathy 54.35 30.59 26 2886 7290 2347883
Maculopathy 54.28 30.59 13 2899 422 2354751
Drug intolerance 54.25 30.59 32 2880 13685 2341488
Palmar-plantar erythrodysaesthesia syndrome 54.17 30.59 22 2890 4179 2350994
Cardiotoxicity 53.41 30.59 16 2896 1231 2353942
Bone lesion 53.30 30.59 14 2898 665 2354508
Pyrexia 53.19 30.59 55 2857 53653 2301520
Deafness 52.22 30.59 19 2893 2682 2352491
Alopecia 51.67 30.59 37 2875 21964 2333209
Weight increased 51.17 30.59 37 2875 22300 2332873
Decreased appetite 48.96 30.59 40 2872 28851 2326322
Aspartate aminotransferase increased 48.76 30.59 29 2883 12583 2342590
Alanine aminotransferase increased 48.43 30.59 30 2882 14002 2341171
Endometriosis 47.80 30.59 13 2899 706 2354467
Pleural disorder 47.02 30.59 9 2903 96 2355077
Nasal disorder 46.76 30.59 11 2901 330 2354843
Lymphoedema 46.06 30.59 14 2898 1131 2354042
Back pain 45.77 30.59 40 2872 31619 2323554
Menopausal symptoms 45.67 30.59 11 2901 366 2354807
Leiomyoma 45.53 30.59 9 2903 115 2355058
Sleep disorder 44.99 30.59 22 2890 6467 2348706
Hypertriglyceridaemia 44.97 30.59 13 2899 883 2354290
Metastases to chest wall 44.94 30.59 8 2904 55 2355118
Ejection fraction decreased 44.28 30.59 17 2895 2784 2352389
Cough 44.21 30.59 40 2872 33077 2322096
Gait disturbance 44.16 30.59 34 2878 22511 2332662
Skin hypopigmentation 44.00 30.59 9 2903 138 2355035
Tumour invasion 43.54 30.59 8 2904 67 2355106
Metastases to peritoneum 43.54 30.59 11 2901 447 2354726
General physical health deterioration 43.22 30.59 28 2884 14111 2341062
Constipation 43.19 30.59 33 2879 21596 2333577
Metastatic neoplasm 43.14 30.59 12 2900 709 2354464
Postmenopausal haemorrhage 42.89 30.59 11 2901 475 2354698
Cervical polyp 42.73 30.59 8 2904 75 2355098
Cognitive disorder 42.64 30.59 20 2892 5361 2349812
Ovarian cyst 42.36 30.59 15 2897 1958 2353215
Blood creatinine decreased 41.90 30.59 11 2901 521 2354652
Haemorrhage 41.67 30.59 25 2887 11014 2344159
Fibrous histiocytoma 41.41 30.59 8 2904 90 2355083
Neuralgia 40.61 30.59 16 2896 2806 2352367
Corneal disorder 40.51 30.59 10 2902 369 2354804
Vitreous detachment 40.38 30.59 10 2902 374 2354799
Tonsillar disorder 40.19 30.59 9 2903 216 2354957
Musculoskeletal chest pain 39.64 30.59 15 2897 2361 2352812
Adenocarcinoma 39.49 30.59 10 2902 410 2354763
Dural arteriovenous fistula 38.85 30.59 6 2906 14 2355159
Hyperhidrosis 38.65 30.59 27 2885 15395 2339778
Blood lactate dehydrogenase increased 37.35 30.59 16 2896 3468 2351705
Weight decreased 37.32 30.59 34 2878 28337 2326836
Metastases to ovary 37.07 30.59 7 2905 69 2355104
Osteoporosis 36.82 30.59 17 2895 4397 2350776
RET gene mutation 36.71 30.59 5 2907 2 2355171
Metastases to pleura 36.38 30.59 8 2904 176 2354997
Polyneuropathy 36.32 30.59 13 2899 1750 2353423
Lymphangioleiomyomatosis 36.23 30.59 6 2906 25 2355148
Metastases to uterus 35.85 30.59 6 2906 27 2355146
Hepatic lesion 35.76 30.59 10 2902 602 2354571
Vein disorder 35.70 30.59 10 2902 606 2354567
Breast cancer in situ 35.61 30.59 9 2903 366 2354807
Peritoneal disorder 35.52 30.59 7 2905 88 2355085
Blood uric acid decreased 35.44 30.59 7 2905 89 2355084
Chronic hepatic failure 35.37 30.59 7 2905 90 2355083
Dizziness 34.46 30.59 46 2866 58619 2296554
Oestradiol abnormal 34.45 30.59 5 2907 6 2355167
Oedema peripheral 34.27 30.59 30 2882 23733 2331440
Vulvovaginal dryness 34.25 30.59 9 2903 428 2354745
Cerebral venous thrombosis 34.23 30.59 9 2903 429 2354744
Headache 34.19 30.59 54 2858 80125 2275048
Porphyria non-acute 33.88 30.59 7 2905 113 2355060
Abdominal pain 33.59 30.59 35 2877 34339 2320834
Blood pressure diastolic increased 33.45 30.59 9 2903 469 2354704
Haematotoxicity 33.37 30.59 11 2901 1156 2354017
Trigger finger 33.32 30.59 9 2903 476 2354697
Blood alkaline phosphatase increased 33.24 30.59 18 2894 6527 2348646
Tympanic membrane disorder 33.13 30.59 6 2906 46 2355127
Pollakiuria 33.00 30.59 15 2897 3741 2351432
Ascites 32.91 30.59 17 2895 5603 2349570
Electrocardiogram QT prolonged 32.90 30.59 19 2893 7795 2347378
Enlarged clitoris 32.79 30.59 6 2906 49 2355124
Lung neoplasm malignant 32.71 30.59 14 2898 3028 2352145
Cellulitis 32.56 30.59 20 2892 9181 2345992
Eosinophil percentage increased 32.42 30.59 7 2905 141 2355032
Acquired gene mutation 32.33 30.59 7 2905 143 2355030
Cardiac failure 32.24 30.59 22 2890 12072 2343101
Oophorectomy 31.54 30.59 7 2905 161 2355012
Thrombocytopenia 31.35 30.59 26 2886 19105 2336068
Congestive cardiomyopathy 31.29 30.59 10 2902 953 2354220
Metastases to muscle 31.22 30.59 5 2907 16 2355157
Neutrophil count increased 31.08 30.59 12 2900 1993 2353180
Agranulocytosis 30.89 30.59 14 2898 3468 2351705
Drug interaction 30.86 30.59 31 2881 29132 2326041

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC L02BA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Anti-estrogens
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D050071 Bone Density Conservation Agents
MeSH PA D004965 Estrogen Antagonists
MeSH PA D020847 Estrogen Receptor Modulators
MeSH PA D006727 Hormone Antagonists
MeSH PA D020845 Selective Estrogen Receptor Modulators
CHEBI has role CHEBI:50837 estrogen antagonist
CHEBI has role CHEBI:50739 estrogen receptor modulator
CHEBI has role CHEBI:50646 bone density conservation agent
CHEBI has role CHEBI:50792 estrogen receptor antagonist
CHEBI has role CHEBI:48422 angiogenesis inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000175826 Estrogen Agonist/Antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infiltrating duct carcinoma of breast indication 408643008 DOID:3008
Carcinoma of female breast indication 447782002
Prevention of Breast Carcinoma indication
Endometrial carcinoma off-label use 254878006 DOID:2871
Malignant tumor of ovary off-label use 363443007 DOID:2394
Hypercalcemia contraindication 66931009 DOID:12678
Leukopenia contraindication 84828003 DOID:615
Bilateral cataracts contraindication 95722004
Deep venous thrombosis contraindication 128053003
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor MODULATOR Ki 7.51 CHEMBL CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 5.36 DRUG MATRIX
Mu-type opioid receptor GPCR Ki 5.15 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.37 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.33 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.40 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.14 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 5.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.84 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.16 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.86 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.88 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.62 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.79 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.44 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.03 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.56 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.20 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 5.73 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 5.24 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.84 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 4.86 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.68 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 5.41 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.61 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.20 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.33 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.45 DRUG MATRIX
Substance-P receptor GPCR Ki 5.07 DRUG MATRIX
Tyrosine-protein kinase Lck Kinase IC50 5.10 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.92 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.53 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 6.04 DRUG MATRIX
Substance-K receptor GPCR Ki 5.91 DRUG MATRIX
B2 bradykinin receptor GPCR Ki 4.92 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.53 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 4.60 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.76 DRUG MATRIX
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Enzyme IC50 4.51 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.50 WOMBAT-PK
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor Ki 7.46 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 4.06 WOMBAT-PK
Estrogen-related receptor gamma Nuclear hormone receptor Ki 7.10 WOMBAT-PK
G-protein coupled estrogen receptor 1 GPCR IC50 7.50 WOMBAT-PK
Estrogen receptor beta Nuclear hormone receptor IC50 5.91 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 5.66 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 7 WOMBAT-PK
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 8.30 WOMBAT-PK
Prostaglandin G/H synthase 2 Enzyme IC50 4.46 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 5.98 CHEMBL
Emopamil-binding protein-like Unclassified Ki 8.55 CHEMBL
Steroid hormone receptor ERR1 Nuclear hormone receptor IC50 6.70 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.80 CHEMBL
Anti-estrogen binding site (AEBS) Enzyme Kd 9 CHEMBL
Progesterone receptor Nuclear hormone receptor IC50 6.89 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.00 DRUG MATRIX
Androgen receptor Transcription factor Ki 4.82 DRUG MATRIX
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 4.81 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.42 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.59 DRUG MATRIX
Transcriptional activator protein luxR Unclassified IC50 4.40 CHEMBL
C-8 sterol isomerase Enzyme Ki 5.82 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 4.92 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 4.66 CHEMBL

External reference:

IDSource
4019939 VUID
N0000148024 NUI
C0039286 UMLSCUI
D00966 KEGG_DRUG
094ZI81Y45 UNII
3299 INN_ID
54965-24-1 SECONDARY_CAS_RN
75959001 SNOMEDCT_US
4019939 VANDF
2281 MMSL
10324 RXNORM
373345002 SNOMEDCT_US
d00381 MMSL
004826 NDDF
CHEMBL83 ChEMBL_ID
CHEMBL786 ChEMBL_ID
DB00675 DRUGBANK_ID
CHEBI:41774 CHEBI
D013629 MESH_DESCRIPTOR_UI
2733526 PUBCHEM_CID
1016 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0144 TABLET 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0274 TABLET 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2472 TABLET 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2473 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0485 TABLET 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0942 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-446 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-447 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-3004 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-4287 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-909 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-910 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63187-976 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63739-269 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 65084-269 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68071-5005 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68382-826 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68382-827 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1881 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1184 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1185 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 71335-0237 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 71335-0893 TABLET 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 71335-1424 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Soltamox HUMAN PRESCRIPTION DRUG LABEL 1 89141-123 LIQUID 20 mg ORAL NDA 21 sections